Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Aug 08, 2018 9:33am
260 Views
Post# 28426244

a couple of weeks to go

a couple of weeks to go
I took time to read the charts and numbers of shares exchanged, comparing two similar period.

In august 2007, the shares of TH went high, and a sell-off occured on august 16 (2007). Down 16%, on near 2 Million shares.

2018 ? The sell-off was much smoother. The lecture I made is that on july 13, TH lost 9%, on 600 000 shares. Less shareholders today sold.

The scenario of 2007 shows that september brings back investors and the share wins back what it lost in july and august.

I think in october, this period will be forgotten for longs.

If TROGARZO got 1 Million in sales for one month in quarter 2. I think we can expect at least 5-6 million for quarter 3. Would that be judged slow penetration of the drug by the market ?

FTV.

Bullboard Posts